17 October 2019

PainChek® partner with Ward Medication Management for national roll out of pain assessment software in residential aged care

Sydney, 17 October 2019 - Listed Australian healthcare innovator PainChek® is partnering with Ward Medication Management (Ward MM) to deliver the federally funded national roll-out of PainChek® technology to the Australian Residential Aged Care market.

PainChek® has developed the world's first smart phone pain assessment and monitoring device, using facial recognition software to accurately assess pain in people who are non-verbal.

Ward MM already has a team of expert Clinical Pharmacists working across residential aged care in Australia. They are currently delivering medication advisory services to reduce medication related harm within residential aged care.

Clinical teams from PainChek® and Ward Medication Management will team up to deliver training to aged care service providers in the use of the technology as part of the national PainChek® roll-out.

"This partnership will help fast track the PainChek® Government funded program with WardMM providing their skilled resources to support the PainChek® roll out across the more than 2000 aged care homes in Australia" commented Philip Daffas, CEO of PainChek Ltd. "Our joint goal is to deliver the PainChek® solution and pain medication training to the nurses and carers who look after the 100,000 Australian aged care residents with dementia within a one-year timeframe" added Daffas.

Engagement of the residential aged care facilities, marketing of the training program and co-ordination of the sessions will be centralised through PainChek. Ward MM will deliver up to 350 PainChek residential aged care training sessions and Ward MM will also implement a "train the trainer" program co-ordinated via its 30 clinical pharmacists.

Ward MM CEO, Fiona Rhody-Nicoll commented, "we are thrilled to be partnering with PainChek® to ensure an optimal roll out of this powerful technology nationally. We see great opportunity for the functionality of PainChek® to support clinical teams to make better informed decisions, particularly for those who are unable to articulate their pain.

The PainChek® technology will allow our own team to translate resident pain-assessment data and insights into actionable medication recommendations for GPs via the Residential Medication Management Review process, delivering a more pro-active and integrated level of care for residents of aged care facilities."

Update on the PainChek Federal Government funded programme

The Company is in regular contact with the Department of Health to finalize the agreement and the delivery schedule for commencement in Q4 C2019 and we thank Minister Richard Colbeck for his ongoing support of the programme. In the meantime, PainChek® has had significant interest from multiple aged care facilities and have already pre-signed up a number of aged care facilities across Australia to ensure the programme can be implemented within the agreed one-year timeframe.

- Ends -

For further information please contact:

Ian Hobson   Philip Daffas
Company Secretary   Managing Director
Tel: +61 8 9388 8290   Tel: +61 406-537-235

www.painchek.com

About Ward MM

A privately-owned business founded in 1997, Ward MM is Australia's leading provider of medication review and quality use of medicines services to the aged and community care sectors. Specialising in geriatric clinical pharmacy, Ward MM provide clinical decision support to doctors and aged care providers. Working alongside, but independently of, supply pharmacies.

Ward MM has a strong commitment to developing the capability and capacity of its team of highly skilled accredited clinical pharmacists, in the key area of geriatric medicine, enabling it to provide highest standards of medication management services.

The company's mission is to eliminate medication-related harm through innovation, technology and quality analysis of medication use and its impact on the elderly.

To find out more visit www.wardmm.com.au.

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit
www.painchek.com

PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.

PainChek® domains of pain assessment that calculates pain severity score.